Advanced search
Publication Cover
Leukemia & Lymphoma Volume 47, 2006 - Issue 12
Submit an article Journal homepage
34
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

Preliminary experience of 18F-fluorodeoxyglucose positron emission tomography in Castleman's disease

Heather Robinson Departments of Haematology
,
Professor H. Miles Prince Departments of Haematology; University of Melbourne, Victoria, AustraliaCorrespondence[email protected]
,
Shakher Ramdave Diagnostic Imaging, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
,
John F. Seymour Departments of Haematology; University of Melbourne, Victoria, Australia
,
Patrick Elliott Department of Haematology, Alfred Hospital, Melbourne, Victoria, Australia
&
Rod Hicks Diagnostic Imaging, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; University of Melbourne, Victoria, Australia
Pages 2664-2666 | Received 16 May 2006, Accepted 28 Jul 2006, Published online: 01 Jul 2009

References

  • Murphy S P, Nathan M A, Karwal M W. FDG-PET appearance of pelvic Castleman's disease. J Nucl Med 1997; 38: 1211–1212
  • Burton C, Ell P, Linch D. The role of PET imaging in lymphoma. Br J Haematol 2004; 126: 772–784
  • Hicks R J, MacManus M P, Seymour J F. Initial staging of lymphoma with positron emission tomography and computed tomography. Sem Nucl Med 2005; 35: 165–175
  • Weihrauch M, Re D, Bischoff S, Dietlein M, Scheidhauer K, Krug F, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002; 81: 20–25
  • Naumann R, Beuthien-Baumann B, Reiss A, Schulze J, Hanel A, Bredow J, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early stage Hodgkin's lymphoma. Br J Cancer 2004; 90: 620–625
  • Hueltenschmidt B, Sautter-Bihl M L, Lang O, Maul F D, Fischer J, Mergenthaler H, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001; 91: 302–310
  • Partridge S, Timothy A, O'Doherty M, Hain S, Rankin S, Mikhaeel N. 2-fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography in the pre-treatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000; 11: 1273–1279
  • Shen Y, Kao A, Yen R. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Oncol Rep 2002; 9: 321–325
  • Kostakoglu L, Leonard J P, Kuji I, Coleman M, Vallabhajosula S, Goldsmith S. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002; 94: 879–888
  • Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finke J, et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001; 91: 889–899
  • Weihrauch M R, Re D, Scheidhauer K, Ansen S, Dietlein M, Bischoff S, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930–2934
  • Juweid M E, Wiseman G A, Vose J M, Ritchie J M, Menda Y, Wooldridge J E, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated international workshop criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23: 4652–4661
  • Blockmans D, Maes A, Stoobants S, Bobbaers H, Mortelmans L. FDG positron emission tomographic scintigraphy can reveal Castleman's disease as a cause of inflammation. Clin Nucl Med 2001; 26: 975–976
  • Kunishima S, Taniguchi H, Koh T, Yamaguchi A, Yamagishi H. F-18 fluorodexyglucose positron emission tomography in mesenterial Castleman's lymphoma. Clin Nucl Med 2001; 26: 789–790
  • Reddy M P, Graham M M. FDG positron emission tomography imaging of thoracic Castleman's disease. Clin Nucl Med 2003; 28: 325–326

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.